Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
WALTHAM, Mass., July 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) is pleased to announce that Canada’s Drug Agency (CDA) has issued a positive reimbursement...
-
WALTHAM, Mass., 09 juill. 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) a le plaisir d’annoncer que l’Agence des médicaments du Canada (AMC) a émis une...
-
EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced...
-
EMPAVELIMD (pegcétacoplan) est le premier traitement autorisé dans le traitement des patients adultes et pédiatriques de 12 ans et plus atteints de glomérulopathie à dépôts de C3 (GC3) ou de...
-
NASP data highlight reduction in disease burden among people living with uncontrolled gout Gamifant (emapalumab) data showed response rates in patients with MAS in Still’s disease across MAS...
-
Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in...
-
WALTHAM, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the U.S. Food and Drug Administration...
-
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced the presentation of four abstracts that...
-
Sobi will present three abstracts that highlights data from its myelofibrosis treatment option at ASCO.
-
FDA has granted Fast Track designation to emapalumab-lzsg for the potential first therapeutic option in patients with MAS